Relationship of angiogenic factors to disease activity and radiographic damage in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 26, Issue 5, 2008, Pages 881-886

  Park, Min Chan ^a   Chung, Soo Jin ^a   Park, Yong Beom ^a   Lee, Soo Kon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Angiogenic factor; Angiogenin; Angiomotin; Disease activity; Endoglin; Radiographic damage; Rheumatoid arthritis; Survivin

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOMOTIN; ENDOGLIN; MESSENGER RNA; PEPTIDES AND PROTEINS; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FIBROBLAST; HUMAN; MALE; OSTEOARTHRITIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ANGIOGENESIS INDUCING AGENTS; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FIBROBLASTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; OSTEOARTHRITIS; RECEPTORS, CELL SURFACE; RIBONUCLEASE, PANCREATIC; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE;

EID: 57249111635     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. VEALE DJ, FEARON U: Inhibition of angiogenic pathways in rheumatoid arthritis: Potential for therapeutic targeting. Best Pract Res Clin Rheumatol 2006; 20: 941-7.
2. BAINBRIDGE J, SIVAKUMAR B, PALEOLOG E: Angiogenesis as a therapeutic target in arthritis: Lessons from oncology. Curr Pharm Des 2006; 12: 2631-44.
3. MARUOTTI N, CANTATORE FP, CRIVELLATO E et al.: Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006; 21: 557-66.
4. BOZOGLU E, DINC A, ERDEM H et al.: Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis. Clin Exp Rheumatol 2005; 23 (Suppl. 38): S42-8.
5. HARADA M, MITSUYAMA K, YOSHIDA H et al.: Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 377-80.
6. SONE H, SAKAUCHI M, TAKAHASHI A et al.: Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci 2001; 69: 1861-9.
7. TAYLOR PC: Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology 2005; 44: 721-8.
8. KNUDSEN LS, OSTERGAARD M, BASLUND B et al: Plasma 1L-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol 2006; 35: 489-91.
9. NAKANO K, OKADA Y, SAITO K et al.: Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum 2004; 50: 2450-8.
10. YAMASHITA A, YONEMITSU Y, OKANO S et al.: Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002; 168: 450-7.
11. TAKAHASHI H, KATO K, MIYAKE K et al.: Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol 2005; 23: 455-61.
12. FERRARA N, HILLAN KJ, GERBER HP et al.: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
13. BADET J: Angiogenin, a potent mediator of angiogenesis: Biological, biochemical and structural properties. Pathol Biol 1999; 47: 345-51.
14. TAN GH, WEI YQ, TIAN L et al.: Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol 2004; 34: 2012-21.
15. LI F: SurvWvin study: what is the next wave? J Cell Physiol 2003; 197: 8-29.
16. HOLMGREN L, AMBROSINO E, BIROT O et al.: A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA 2006; 103: 9208-13.
17. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
18. FUCHS HA: The use of the Disease Activity Score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol 1993; 20: 1863-6.
19. LARSEN A, EDGREN J, HARJU E et al.: Inter-observer variation in the evaluation of radiologic changes of rheumatoid arthritis. Scand J Rheumatol 1979; 8: 109-12.
20. LIOTE F, CHAMPY R, MOENNER M et al.: Elevated angiogenin levels in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblasts. Clin Exp Immunol 2003; 132: 163-8.
21. SZEKANECZ Z, HAINES GK, HARLOW LA et al.: Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-heta 1 in rheumatoid arthritis: Possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995; 76: 187-94.
22. TROYANOVSKY B, LEVCHENDO T, MANSSON G et al.: Angiomotin, an angiostatin vinding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001; 152: 1247-54.
23. BUCKLEY CD: Why do leucocytes accumulate within chronically inflamed joints? Rheumatology 2003; 42: 1433-44.
24. BOKAREWA M, LINDBLAD S, BOKAREW D et al.: Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 2005; 7: 349-58.
25. MARKHAM T, MULLAN R, GOLDEN-MASON L et al.: Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006; 54: 1003-12.